Mouse group

n

Glucose

Insulin

E2

Raw

BW-N


Raw

BW-N

Raw

BW-N

L-C

6

173.7±28.8

6.7±1.7

78.2±22.6

3.0±1.1

2.4±1.1

0.1 ± 0.0

L-I

7

186.7±21.7

7.1±1.3

95.6 ±15.4

4.3±1.5

7.5 ±7.8

0.3 ± 0.3

L-II

7

162.5±19.8

6.5±0.9

96.1 ± 39.0

4.1± 1.6

4.1 ± 4.0

0.2 ± 0.2

DIO-C

11

228.8±89.5

6.4±2.8

85.1±29.3

2.8±1.1

6.2±8.8

0.2 ± 0.0

DIO-I

7

216.9±58.6

7.0±3.2

120.6 ±48.1

4.0±1.9

4.1 ±2.1

0.1 ± 0.0

DIO-II

7

174.9±51.3

6.4±1.5

70.6 ±13.2

2.6± 0.4

4.3 ±3.1

0.2 ± 0.1

DIO-MT

3

333.9±252.9

14.3±11.7

70.6± 0.0

2.9± 0.2

4.7± 3.2

0.2 ± 0.2
Term definitions:
DIO-MT: DIO-mice hosting mammary tumors.
Raw: levels of plasmatic parameters not adjusted to body weight [(glucose, mg/dL); (insulin, pmol/L) and (E2, estradiol, pg/mL)].
BW-N: levels of plasmatic parameters normalized to body weight in grams [(glucose, mg/dL/g), (insulin, pmol/L/g) and (estradiol, pg/mL/g).
Table 3: Effects of leptin antagonist treatment on plasmatic levels of glucose, insulin and estradiol in DMBA-mice.